LDX logo

Lumos Diagnostics Holdings Limited Stock Price

ASX:LDX Community·AU$125.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

LDX Share Price Performance

AU$0.16
0.12 (272.09%)
AU$0.16
0.12 (272.09%)
Price AU$0.16

LDX Community Narratives

There are no narratives available yet.

Recent LDX News & Updates

Lumos Diagnostics Holdings Limited's (ASX:LDX) 71% Share Price Surge Not Quite Adding Up

Aug 30
Lumos Diagnostics Holdings Limited's (ASX:LDX) 71% Share Price Surge Not Quite Adding Up

There's No Escaping Lumos Diagnostics Holdings Limited's (ASX:LDX) Muted Revenues Despite A 154% Share Price Rise

Jul 16
There's No Escaping Lumos Diagnostics Holdings Limited's (ASX:LDX) Muted Revenues Despite A 154% Share Price Rise

Lumos Diagnostics Holdings Limited (ASX:LDX) Shares Fly 29% But Investors Aren't Buying For Growth

May 09
Lumos Diagnostics Holdings Limited (ASX:LDX) Shares Fly 29% But Investors Aren't Buying For Growth

Lacklustre Performance Is Driving Lumos Diagnostics Holdings Limited's (ASX:LDX) 29% Price Drop

Mar 07
Lacklustre Performance Is Driving Lumos Diagnostics Holdings Limited's (ASX:LDX) 29% Price Drop

Lumos Diagnostics Holdings Limited's (ASX:LDX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 20
Lumos Diagnostics Holdings Limited's (ASX:LDX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Lumos Diagnostics Holdings Limited Key Details

US$12.4m

Revenue

US$4.7m

Cost of Revenue

US$7.7m

Gross Profit

US$14.9m

Other Expenses

-US$7.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.0091
Gross Margin
61.93%
Net Profit Margin
-57.93%
Debt/Equity Ratio
0%

Lumos Diagnostics Holdings Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Adequate balance sheet with low risk.

3 Risks
2 Rewards

About LDX

Founded
2018
Employees
n/a
CEO
Douglas Ward
WebsiteView website
lumosdiagnostics.com

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.8%
  • 3 Months: 8.3%
  • 1 Year: 17.8%
  • Year to Date: 15.4%
Over the last 7 days, the market has remained flat, although notably the Utilities sector gained 3.1% in that time. Meanwhile, the market is actually up 18% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›